Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Queensland Health
Daiichi Sankyo
Julphar
Federal Trade Commission
Fish and Richardson
US Army
Novartis
McKesson

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,915,888

« Back to Dashboard

Which drugs does patent 8,915,888 protect, and when does it expire?

Patent 8,915,888 protects ADLYXIN and is included in one NDA.

This patent has twenty patent family members in sixteen countries.
Summary for Patent: 8,915,888
Title:Dosing and drive mechanism for drug delivery device
Abstract: The present invention relates to drive mechanisms suitable for use in drug delivery devices, in particular pen-type injectors, wherein a number of pre-set doses of medicinal product can be administered. In particular, the present invention relates to such drug delivery devices where a user may activate the drug delivery device.
Inventor(s): Boyd; Malcolm (Leamington Spa, GB), Letham; Richard (Kingston Upon Thames, GB), Plumptre; David (Worcerstershire, GB), Veasey; Robert (Leamington Spa, GB), May; James (Earlsdon, GB), Jones; Matthew (Warwickshire, GB), Ghazaros; Samuel (Bristol, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/466,581
Patent Claim Types:
see list of patent claims
Delivery; Device; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,915,888

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Subscribe
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,915,888

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06023961Nov 17, 2006

International Patents Family Members for US Patent 8,915,888

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Malaysia 151515 ➤ Subscribe
Mexico 2009005098 ➤ Subscribe
South Korea 101422458 ➤ Subscribe
South Korea 20090083463 ➤ Subscribe
Japan 5286273 ➤ Subscribe
Japan 2010509956 ➤ Subscribe
Israel 198755 ➤ Subscribe
Hong Kong 1140156 ➤ Subscribe
European Patent Office 2083889 ➤ Subscribe
European Patent Office 1923085 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Deloitte
Boehringer Ingelheim
Daiichi Sankyo
Queensland Health
Teva
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot